Colin Broom
Chief Executive Officer at Pulmotect, Inc.
Net worth: 1 944 $ as of 2023-07-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Steven Gelone | M | 56 |
Shire ViroPharma, Inc.
 Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | 17 years |
| Charles Rowland | M | 65 |
Nabriva Therapeutics GmbH
 Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria.
Shire ViroPharma, Inc.
Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | 16 years |
| Daniel Burgess | M | 62 |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | 8 years |
| Brenton Scott | M | - |
Pulmotect, Inc.
 Pulmotect, Inc. BiotechnologyHealth Technology Pulmotect, Inc. develops clinical stage, novel, pathogen-agnostic, inhaled compound for the prevention and early treatment of acute, severe viral and bacterial respiratory infections. It provides safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague). The company was founded by Brenton Scott and Magnus Hook in 2007 and is headquartered in Houston, TX. | 17 years |
| Stephen Webster | M | 63 |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | 8 years |
| Mark White | M | 57 |
Faculty of Pharmaceutical Medicine
The Royal College of Physicians
| - |
| Paul Blake | M | 76 |
Faculty of Pharmaceutical Medicine
The Royal College of Physicians
| - |
| Helen Torley | M | 61 |
The Royal College of Physicians
| 9 years |
| Dominic Smethurst | M | 50 |
Faculty of Pharmaceutical Medicine
The Royal College of Physicians
| - |
| Steve Knowles | M | - |
Faculty of Pharmaceutical Medicine
The Royal College of Physicians
| - |
| Theodore Schroeder | M | 69 | 6 years | |
| Robert Eckert | M | 69 | 21 years | |
| Magnus Hook | M | - |
Pulmotect, Inc.
Pulmotect, Inc. BiotechnologyHealth Technology Pulmotect, Inc. develops clinical stage, novel, pathogen-agnostic, inhaled compound for the prevention and early treatment of acute, severe viral and bacterial respiratory infections. It provides safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague). The company was founded by Brenton Scott and Magnus Hook in 2007 and is headquartered in Houston, TX. | 17 years |
| Curt Mikael von Euler-Chelpin | M | 71 |
The Royal College of Physicians
| - |
| Christopher Ball | M | - |
The Royal College of Physicians
| - |
| Sanjay Rajpara | M | - |
The Royal College of Physicians
| - |
| Abdur Rahman Khan | M | 90 |
The Royal College of Physicians
| - |
| Pyarelal Baburam Tiwari | M | 77 |
The Royal College of Physicians
| - |
| Wai Ming Lam | M | 66 |
The Royal College of Physicians
| 35 years |
| Lindsey Rolfe | M | 56 |
The Royal College of Physicians
| - |
| Stuart Ungar | M | 80 |
The Royal College of Physicians
| - |
| Athasit Vejjajiva | M | 88 |
The Royal College of Physicians
| - |
| Mike Anderson | M | - |
The Royal College of Physicians
| - |
| Ashish Soman | M | - |
The Royal College of Physicians
| - |
| Rupert Vessey | M | 59 |
The Royal College of Physicians
| - |
| Ian Gourley | M | - |
The Royal College of Physicians
| - |
| Hilary McElwaine-Johnn | M | - |
The Royal College of Physicians
| - |
| Ray Tallis | M | - |
The Royal College of Physicians
| - |
| Chun Kwan Chow | M | 69 |
The Royal College of Physicians
| 39 years |
| Karen Atkin | M | 58 |
The Royal College of Physicians
| - |
| Christopher Burton | M | - |
The Royal College of Physicians
| - |
| Arvind Balakrishna Kasaragod | M | - |
The Royal College of Physicians
| - |
| Ash Soman | M | - |
The Royal College of Physicians
| - |
| Bipin Mistry | M | - |
The Royal College of Physicians
| - |
| Monica Shaw | M | 46 |
The Royal College of Physicians
| - |
| Essra Ridha | M | 41 |
The Royal College of Physicians
| - |
| Richard Philipson | M | 60 |
The Royal College of Physicians
| - |
| Man Yung Cheng | M | 74 |
The Royal College of Physicians
| 44 years |
| Rosh Dias | M | - |
The Royal College of Physicians
| - |
| Ravi Rao | M | 55 |
The Royal College of Physicians
| - |
| Edwin Tucker | M | 52 |
The Royal College of Physicians
| - |
| Paul Kenna | M | - |
The Royal College of Physicians
| - |
| Alexandra Sinclair | M | - |
The Royal College of Physicians
| - |
| Omar Khwaja | M | 54 |
The Royal College of Physicians
| 25 years |
| Preetinder Singh Joshi | M | 75 |
The Royal College of Physicians
| 46 years |
| Warren Cooper | M | 71 |
The Royal College of Physicians
| - |
| Stephen D. Wise | M | - |
The Royal College of Physicians
| - |
| Herman Waldmann | M | - |
The Royal College of Physicians
| - |
| Richard Fuller | M | - |
The Royal College of Physicians
| - |
| Ka Wah Hui | M | 60 |
The Royal College of Physicians
| - |
| Martin Edwards | M | 68 |
The Royal College of Physicians
| - |
| Derek Miller | M | - | 21 years | |
| Peter Richardson | M | 64 |
The Royal College of Physicians
| - |
| David Shapiro | M | 69 |
The Royal College of Physicians
| - |
| Ken Cunningham Cunningham | M | 71 |
The Royal College of Physicians
| - |
| Harry Solomon | M | 87 |
The Royal College of Physicians
| - |
| Ik King Tiong | M | 74 |
The Royal College of Physicians
| 47 years |
| Cheok Peng Lim | M | 77 |
The Royal College of Physicians
| 47 years |
| Henry Y. Pan | M | 77 |
The Royal College of Physicians
| - |
| Freda Lewis-Hall | M | 69 |
The Royal College of Physicians
| - |
| Lesley Russell | M | 63 |
The Royal College of Physicians
| 37 years |
| Andrew Allen | M | 57 |
The Royal College of Physicians
| - |
| Frank Armstrong | M | 67 |
The Royal College of Physicians
| 40 years |
| John Anderson | M | - |
The Royal College of Physicians
| - |
| John Bonnar | M | - |
The Royal College of Physicians
| - |
| Akshay Vaishnaw | M | 61 |
The Royal College of Physicians
| - |
| Samuel N. Marcus | M | - |
The Royal College of Physicians
| - |
| Ramesh Kancharla | M | 62 |
The Royal College of Physicians
| - |
| Michael McDonald | M | - |
The Royal College of Physicians
| - |
| Kim Heung Tan | M | 62 |
The Royal College of Physicians
| 35 years |
| Simon Long | M | - |
The Royal College of Physicians
| - |
| Caroline Dumas | M | - |
The Royal College of Physicians
| - |
| Felicity Gabbay | M | 72 |
The Royal College of Physicians
| - |
| Alan Keith Boyd | M | 70 |
The Royal College of Physicians
| - |
| Emmet B. Keeffe | M | - |
The Royal College of Physicians
| - |
| Peter Dewis | M | - |
The Royal College of Physicians
| - |
| Emiko Terasaki | M | - |
The Royal College of Physicians
| 25 years |
| Swee Huat Phua | M | 70 |
The Royal College of Physicians
| - |
| Dawn Viveash | M | 68 |
The Royal College of Physicians
| - |
| Leo Kearns | M | - |
The Royal College of Physicians
| - |
| Kemal Malik | M | 61 |
The Royal College of Physicians
| - |
| Edwin Graham Meek | M | 76 |
The Royal College of Physicians
| - |
| Alan Suggett | M | 80 |
The Royal College of Physicians
| - |
| Keng Hwang Teh | M | 71 |
The Royal College of Physicians
| - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Vin Milano Milano | M | 60 |
Shire ViroPharma, Inc.
Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | 18 years |
| David Garrett | M | 44 |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | 4 years |
| Robert L. Crotty | M | 50 |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | 3 years |
| Mark Corrigan | M | 66 |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | 7 years |
| John Naftzger | M | 57 | 6 years | |
| Francois Nader | M | 67 | 7 years | |
| Kathryn Falberg | F | 63 | 6 years | |
| Michael Kelly | M | 67 | 14 years | |
| Michel de Rosen | M | 73 |
Shire ViroPharma, Inc.
Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | 8 years |
| Pierre Legault | M | 63 |
Hoechst Marion Roussel, Inc.
| 4 years |
| Gary Sender | M | 62 |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | 5 years |
| Ralf Schmid | M | 57 |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | 10 years |
| George Harrison Talbot | M | 76 |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | 12 years |
| George Morrow | M | 72 | 10 years | |
| Dominique Monnet | M | 65 | 11 years | |
| James Daly | M | 63 | 9 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 75 | 75.00% |
| United States | 17 | 17.00% |
| Ireland | 11 | 11.00% |
| Austria | 9 | 9.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Colin Broom
- Personal Network
